BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 37652543)

  • 1. A Prostate-Specific Membrane Antigen PET-Based Approach for Improved Diagnosis of Prostate Cancer in Gleason Grade Group 1: A Multicenter Retrospective Study.
    Zhang J; Kang F; Gao J; Jiao J; Quan Z; Ma S; Li Y; Guo S; Li Z; Jing Y; Zhang K; Yang F; Han D; Wen W; Zhang J; Ren J; Wang J; Guo H; Qin W
    J Nucl Med; 2023 Nov; 64(11):1750-1757. PubMed ID: 37652543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establishment and prospective validation of an SUV
    Jiao J; Kang F; Zhang J; Quan Z; Wen W; Zhao X; Ma S; Wu P; Yang F; Guo W; Yang X; Yuan J; Shi Y; Wang J; Qin W
    Theranostics; 2021; 11(17):8396-8411. PubMed ID: 34373749
    [No Abstract]   [Full Text] [Related]  

  • 3. The use of
    Yang J; Tang Y; Zhou C; Zhou M; Li J; Hu S
    Prostate; 2023 Apr; 83(5):430-439. PubMed ID: 36544382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The PRIMARY Score: Using Intraprostatic
    Emmett L; Papa N; Buteau J; Ho B; Liu V; Roberts M; Thompson J; Moon D; Sheehan-Dare G; Alghazo O; Agrawal S; Murphy D; Stricker P; Hope TA; Hofman MS
    J Nucl Med; 2022 Nov; 63(11):1644-1650. PubMed ID: 35301240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reproducibility and Accuracy of the PRIMARY Score on PSMA PET and of PI-RADS on Multiparametric MRI for Prostate Cancer Diagnosis Within a Real-World Database.
    Emmett L; Papa N; Counter W; Calais J; Barbato F; Burger I; Eiber M; Roberts MJ; Agrawal S; Franklin A; Xue A; Rasiah K; John N; Moon D; Frydenberg M; Yaxley J; Stricker P; Wong K; Coughlin G; Gianduzzo T; Kua B; Ho B; Nguyen A; Liu V; Lee J; Hsiao E; Sutherland T; Perry E; Fendler WP; Hope TA
    J Nucl Med; 2024 Jan; 65(1):94-99. PubMed ID: 38050155
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Yang J; Li J; Xiao L; Zhou M; Fang Z; Cai Y; Tang Y; Hu S
    Cancer Imaging; 2023 Sep; 23(1):81. PubMed ID: 37667341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined Utility of
    Kalapara AA; Ballok ZE; Ramdave S; O'Sullivan R; Ryan A; Konety B; Grummet JP; Frydenberg M
    Eur Urol Oncol; 2022 Jun; 5(3):314-320. PubMed ID: 33741337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How to make clinical decisions to avoid unnecessary prostate screening in biopsy-naïve men with PI-RADs v2 score ≤ 3?
    Zhang Y; Zeng N; Zhang F; Huang Y; Tian Y
    Int J Clin Oncol; 2020 Jan; 25(1):175-186. PubMed ID: 31473884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PI-RADS-Based Segmented Threshold of PSMA-PET SUVmax Is Better than Traditional Fixed Threshold for Diagnosing Clinically Significant Prostate Cancer Especially for PI-RADS 3 Lesions.
    Meng X; Ma W; Zhang J; Quan Z; Zhang M; Ye J; Shu J; Ren J; Qin W; Kang F; Wang J
    Mol Imaging Biol; 2023 Oct; 25(5):887-896. PubMed ID: 37490189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a nomogram combining multiparametric magnetic resonance imaging and PSA-related parameters to enhance the detection of clinically significant cancer across different region.
    Zhou Z; Liang Z; Zuo Y; Zhou Y; Yan W; Wu X; Ji Z; Li H; Hu M; Ma L
    Prostate; 2022 Apr; 82(5):556-565. PubMed ID: 35098557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association Between Prostate Imaging Reporting and Data System (PI-RADS) Score for the Index Lesion and Multifocal, Clinically Significant Prostate Cancer.
    Stabile A; Dell'Oglio P; De Cobelli F; Esposito A; Gandaglia G; Fossati N; Brembilla G; Cristel G; Cardone G; Deho' F; Losa A; Suardi N; Gaboardi F; Del Maschio A; Montorsi F; Briganti A
    Eur Urol Oncol; 2018 May; 1(1):29-36. PubMed ID: 31100225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deep learning model for the detection of prostate cancer and classification of clinically significant disease using multiparametric MRI in comparison to PI-RADs score.
    Yang C; Li B; Luan Y; Wang S; Bian Y; Zhang J; Wang Z; Liu B; Chen X; Hacker M; Li Z; Li X; Wang Z
    Urol Oncol; 2024 May; 42(5):158.e17-158.e27. PubMed ID: 38388243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic versus Targeted Magnetic Resonance Imaging/Ultrasound Fusion Prostate Biopsy among Men with Visible Lesions.
    Patel HD; Koehne EL; Shea SM; Fang AM; Gorbonos A; Quek ML; Flanigan RC; Goldberg A; Rais-Bahrami S; Gupta GN
    J Urol; 2022 Jan; 207(1):108-117. PubMed ID: 34428091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiparametric Magnetic Resonance Imaging,
    Kubihal V; Sharma S; Kumar R; Seth A; Kumar R; Kaushal S; Sarangi J; Gupta R; Das CJ
    Indian J Nucl Med; 2021; 36(4):362-370. PubMed ID: 35125753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Value of
    Shi J; Li D; Chen M; Fu Y; Peng S; Zhang Q; Liang J; Lu Q; Lu J; Ai S; Wang F; Qiu X; Guo H
    J Nucl Med; 2024 Apr; 65(4):555-559. PubMed ID: 38485278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study.
    Emmett L; Buteau J; Papa N; Moon D; Thompson J; Roberts MJ; Rasiah K; Pattison DA; Yaxley J; Thomas P; Hutton AC; Agrawal S; Amin A; Blazevski A; Chalasani V; Ho B; Nguyen A; Liu V; Lee J; Sheehan-Dare G; Kooner R; Coughlin G; Chan L; Cusick T; Namdarian B; Kapoor J; Alghazo O; Woo HH; Lawrentschuk N; Murphy D; Hofman MS; Stricker P
    Eur Urol; 2021 Dec; 80(6):682-689. PubMed ID: 34465492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can the addition of clinical information improve the accuracy of PI-RADS version 2 for the diagnosis of clinically significant prostate cancer in positive MRI?
    Polanec SH; Bickel H; Wengert GJ; Arnoldner M; Clauser P; Susani M; Shariat SF; Pinker K; Helbich TH; Baltzer PAT
    Clin Radiol; 2020 Feb; 75(2):157.e1-157.e7. PubMed ID: 31690449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structured approach to resolving discordance between PI-RADS v2.1 score and targeted prostate biopsy results: an opportunity for quality improvement.
    Arcot R; Sekar S; Kotamarti S; Krischak M; Michael ZD; Foo WC; Huang J; Polascik TJ; Gupta RT
    Abdom Radiol (NY); 2022 Aug; 47(8):2917-2927. PubMed ID: 35674785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic value of combining PI-RADS v2.1 with PSAD in clinically significant prostate cancer.
    Wei X; Xu J; Zhong S; Zou J; Cheng Z; Ding Z; Zhou X
    Abdom Radiol (NY); 2022 Oct; 47(10):3574-3582. PubMed ID: 35788882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.